Cardiac arrest & resuscitation
Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial
Authors' conclusion
In patients with OHCA and refractory VF who are pretreated with epinephrine and amiodarone, add-on bolus infusion of landiolol 20 mg did not lead to a shorter time to sustained ROSC compared with placebo. Landiolol might be associated with bradycardia and asystole.
Study context
- Population
- Out-of-hospital cardiac arrest (OHCA) with recurrent or refractory ventricular fibrillation (VF) (≥3 defibrillation attempts, last rhythm shockable), pretreated with epinephrine and amiodarone
- Participants
- 36 participants
- Comparison
- Add-on landiolol vs placebo
- Landiololn = 19
- Placebon = 17reference
- Primary endpoint
- Time from trial drug infusion to sustained ROSC
Methodological detailsdouble-blind, placebo-controlled, pilot
- Double-blind
- Placebo-controlled
- Pilot
Primary result
As reported in the abstract
Further findings
Sustained ROSC
Sustained return of spontaneous circulation (ROSC)
- Numerically lower with landiolol
Safety
Asystole within 15 min of trial drug infusion
Asystole within 15 min of trial drug infusion
- Significantly more often with landiolol
Original publication
Landiolol for refractory ventricular fibrillation in out-of-hospital cardiac arrest: A randomized, double-blind, placebo-controlled, pilot trial. Resuscitation. Published 10 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →